Blog

Mar 11, 2025, 06:50

Yan Leyfman: Our latest publication on emerging therapeutic developments in T-cell lymphomas

Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post by CancerNetwork, on X, adding:

“Excited to share our latest publication published in ONCOLOGY from the MedNewsWeek team on emerging therapeutic developments in T-cell lymphomas! Inspired by Dr. Jasmine Zain’s (Memorial Sloan Kettering Cancer Center) insightful keynote presentation.

A big thank you to CancerNetwork for featuring this important work!

Revolutionizing Cancer Treatment: CAR T-Cell Therapy in T-Cell Lymphomas

Chimeric Antigen Receptor (CAR) T-cell therapy is a game-changer in oncology, showing promise against hematological malignancies, including challenging T-cell lymphomas. This innovative approach involves engineering a patient’s T cells to recognize and destroy cancer cells.

The Challenge: Treating aggressive T-cell lymphomas like Peripheral T-cell Lymphoma (PTCL) is tough. The complexities of subtypes such as Angioimmunoblastic T-cell Lymphoma (AITL) and Anaplastic Large-cell Lymphoma (ALCL) create hurdles, including severe toxicities and limited treatment options.

Pioneering Research: Dr. Jasmine Zain (Memorial Sloan Kettering Cancer Center) is leading the charge, exploring how epigenetic components in PTCL can guide treatment strategies. Her insights, shared at MedNews Week, emphasize personalized immunotherapeutics and novel therapies like EZH2 inhibitors and HDAC inhibitors.

Hope for the Future: While CAR T-cell therapy faces challenges in T-cell lymphomas, advancements in understanding genetic mutations (e.g., IDH2, TET2, TP53) are paving the way for new, targeted treatments. Continued research and clinical trials are vital to improving outcomes for patients with limited options.”

Quoting CancerNetwork‘s post:

“Read the latest on updates treatment options for peripheral T-cell lymphoma in the March issue of ONCOLOGY.”